AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Abacus Health Products CEO Perry Antelman and Rob Gronkowski to Present at Cowen’s 2nd Annual Boston Cannabis Conference

November 6, 2019 GMT
Abacus Health Products CEO Perry Antelman and Rob Gronkowski to Present at Cowen’s 2nd Annual Boston Cannabis Conference
Abacus Health Products CEO Perry Antelman and Rob Gronkowski to Present at Cowen’s 2nd Annual Boston Cannabis Conference

WOONSOCKET, R.I. & TORONTO--(BUSINESS WIRE)--Nov 6, 2019--

Abacus Health Products, Inc. (CSE:ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) today announced that it will participate in the 2 nd Annual Boston Cannabis Conference presented by Cowen. The event will be held November 11 th – 13 th 2019 at The Intercontinental Hotel in Boston, MA.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191106005528/en/

Abacus Health Products and Rob Gronkowski to participate in Cowen’s Boston Cannabis Conference (Graphic: Business Wire)

Abacus’ CEO Perry Antelman will participate in a panel discussion on CBD alongside other leading CBD companies. Abacus has also confirmed Cowen CEO Jeffrey Solomon will sit down with Rob Gronkowski for a fireside chat that will highlight Abacus’ recent partnership with the three-time football world champion. Abacus will be available for 1-on-1 meetings throughout the conference.

About Abacus Health Products, Inc.

Abacus is engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from the Cannabis sativa L plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: CBD CLINIC™, marketed to the professional practitioner market, and CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility.

To learn more about Abacus, visit www.abacushp.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20191106005528/en/

CONTACT: For further information:

Hank Hague, Chief Financial Officer

Email:investorrelations@abacushp.com

Or

Bill Mitoulas, Investor Relations

Email:bill@abacushp.com

Office: 1.416.479.9547

KEYWORD: RHODE ISLAND MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY SPORTS FOOTBALL HEALTH SPECIALTY CONSUMER OTHER CONSUMER RETAIL

SOURCE: Abacus Health Products, Inc.

Copyright Business Wire 2019.

PUB: 11/06/2019 07:57 AM/DISC: 11/06/2019 07:57 AM

http://www.businesswire.com/news/home/20191106005528/en